(19) demonstrated that folate-targeted Toll-like receptor 7 agonist (FA-TLR7-1A) can reprogram immunosuppressive M2 macrophages into pro-inflammatory M1 macrophages by targeted activation of the TLR7 signaling pathway, thereby breaking the immunosuppressive state of the tumor microenvironment and enhancing the efficacy of CAR-T cells. The gene discussed is TLR7; the disease is neoplasm.